Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company's website. Key financial information as of December 31, 2023 Crossject's financial results for the year ending December 31, 2023 have now been fully audited with a minor change of -0.17 M€ compared to the previous report, released on March 29 and available here. All reports relating to financials for the year 2023 will be available on the Crossject website from April 30 and are also presented in the appendices below. The table below summarizes our income statement for the years ending 31 December 2023 and 2022: € thousands, as of 31 December 2023 2022 Operating income 12 826 9 718 Operating expenses -24 626 -23 005 Purchase of raw material and supplies -1 595 -498 Other purchases and external expenses -8 869 -8 116 Personal expenses -7 713 -7 424 Taxes and duties -267 -176 Depreciation, amortisation and provision -5 688 -6 358 Other expenses -494 -433 Operating profit/loss -11 800 -13 288 Financial income/expense -497 -319 Exceptional income/expense 791 228 Corporate tax 2 867 2 222 Net profit/loss -8 638 -11 157 About Crossject Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company developing products for emergencies harnessing its proprietary needle-free auto-injector technology ZENEO. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company's award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company's other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks. For further information, please contact: Investors Natasha DrapeauCohesion Bureau+41 76 823 75 MediaSophie BaumontCohesion Bureau+33 6 27 74 74   APPENDICES INCOME STATEMENT (in K€) 31/12/2023 31/12/2022 VARIATION   Revenue 145 954 -809 Stored production 591 348 243 Capitalised production 3 594 6 104 -2 510 Subsidies 133 5 128 Reversals of provisions and transfers of expenses 2 632 445 2 187 Other income 6 231 1 861 4 370 Operating income 13 326 9 717 3 609 Purchases of raw materials and other supplies 1 625 1 002 623 Change in inventory (raw materials and other supplies) -29 -505 476 Other purchases and external expenses 8 869 8 115 754 Taxes and duties 267 177 90 Personnel expenses 7 714 7 425 289 Depreciation, amortisation 4 504 5 263 -759 Other provisions 1 682 1 095 587 Other expenses 494 433 61 Operating expenses 25 126 23 005 2 121 Operating profit/loss -11 800 -13 288 1 488 Financial income/expense -497 -319 -178 Exceptional income/expense 791 228 563 Research Tax Credit 2 867